A New Frontier in the Co-Management of Thyroid Eye Disease

Thyroid eye disease, also known as Graves’ orbitopathy, is a potentially serious, progressive autoimmune disease that most often occurs in people with hyperthyroidism, ie, Graves’ disease. Kimberley Cockerham, MD, FACS, moderates this series of six, paired conversations between endocrinologist Terry J. Smith, MD, and eye specialists Wendy W. Lee, MD, and Raymond Douglas, MD, PhD, to explore current and emerging treatment options for thyroid eye disease. In these conversations, faculty review the current understanding of the burden and pathophysiology of thyroid eye disease—including treatment targets—and describe the key features of thyroid eye disease and how they are different from other diseases of the eye. Faculty explore the role of nonpharmacologic, pharmacologic, and surgical options for thyroid eye disease and discuss how to implement strategies that help patients with thyroid eye disease improve their quality of life.
• Burden of Disease
• Pathophysiology
• Patient Evaluation
• Nonpharmacologic Treatment
• Pharmacologic Treatment
• Clinical Trial Experience
• Surgical and Radiation Treatment